Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 2/20 | 0.65 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.65 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL310728 | 0.85 | P2RX3 (0.68) | P2RX3P2RX2HDAC4HDAC6HRH3 | |
| SCHEMBL10243279 | 0.80 | P2RX3 (0.61) | P2RX3P2RX2HDAC4HDAC6L3MBTL1 | |
| SCHEMBL406256 | 0.79 | P2RX3 (0.73) | P2RX3P2RX2HDAC4HDAC6HRH3 | |
| SCHEMBL10187943 | 0.79 | P2RX3 (0.73) | P2RX3P2RX2HDAC4HDAC6L3MBTL1 | |
| SCHEMBL406888 | 0.79 | P2RX3 (0.73) | P2RX3P2RX2HDAC4HDAC6HRH3 | |
| SCHEMBL405831 | 0.79 | P2RX3 (0.73) | P2RX3P2RX2HDAC4HDAC6L3MBTL1 | |
| SCHEMBL13774506 | 0.79 | P2RX3 (0.66) | P2RX3P2RX2HDAC4HDAC6L3MBTL1 | |
| SCHEMBL12757547 | 0.79 | P2RX3 (0.61) | P2RX3P2RX2HDAC4HDAC6HRH3 | |
| SCHEMBL13014788 | 0.79 | P2RX3 (0.61) | P2RX3P2RX2HDAC4HDAC6 | |
| SCHEMBL14207520 | 0.79 | P2RX3 (0.61) | P2RX3P2RX2HDAC4HDAC6HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065681-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-03-17 | — | — | US | claimed |
| US-20150266822-A1 | Amide Compounds, Compositions And Uses Thereof | RENOVIS, INC. | 2015-09-24 | — | — | US | disclosed |
| US-20150266822-A1 | Amide Compounds, Compositions And Uses Thereof | RENOVIS, INC. | 2015-09-24 | — | — | US | disclosed |
| US-8946439-B2 | Amide compounds, compositions and uses thereof | EVOTEC AG (DE) | 2015-02-03 | — | — | US | disclosed |
| US-8946439-B2 | Amide compounds, compositions and uses thereof | EVOTEC AG (DE) | 2015-02-03 | — | — | US | disclosed |
| US-20110065681-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-03-17 | — | — | US | disclosed |
| US-20110065681-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-03-17 | — | — | US | disclosed |
| US-20110065681-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065681-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | IL1B, ADORA2B, AVPR1B | P2RX3 219/4885P2RX2 259/4885HDAC4 1757/4885 |
| US-20150266822-A1 | Amide Compounds, Compositions And Uses Thereof | IL1B, ADORA2B, AVPR1B | P2RX3 219/4885P2RX2 259/4885HDAC4 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.